Stonepine Capital Management’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Stonepine Capital Management’s Portfolio JNP Stock Details JNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-228,392	Closed	-$1.28M	–	24
2016 Q4	$1.28M	Buy	228,392 +54,425	+31%	+$299K	0.76%	21
2016 Q3	$966K	Buy	+173,967	New	+$1.15M	0.79%	14

Other funds holding JNP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Algert Global San Francisco, California $8.43B AUM 80.94% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Stonepine Capital Management's JNP Position: Q1 2017 in Review

Stonepine Capital Management sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q1 2017, closing a stake of 228,392 shares — an estimated $1.28M sold.

Stonepine Capital Management first reported a position in JNP in Q3 2016 and held it in 2 quarters. The position peaked at $1.28M in Q4 2016. 38 funds tracked by Wall St. Rank hold JNP as of Q1 2017.

Stonepine Capital Management reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
Stonepine Capital Management sold 228,392 Juniper Pharmaceuticals, Inc. Common Stock shares in Q1 2017, an estimated $1.28M.
Stonepine Capital Management first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 2 quarters.
Stonepine Capital Management's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $1.28M in Q4 2016.
38 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q1 2017.

Based on Stonepine Capital Management's 13F filing for Q1 2017, filed 12 May 2017.